| Literature DB >> 28893195 |
Xiaoguang He1,2,3, Mingyu Xie1,2,3, Siping Li1,2,3, Junqin Ye1,2,3, Qi Peng1,2,3, Qiang Ma1,2,3, Xiaomei Lu4,5,6, Baimao Zhong7,8,9.
Abstract
BACKGROUND: Bacterial pathogens are a major cause of childhood community acquired lower respiratory tract infections (CA-LRTIs), and few data described the impact of antimicrobial resistance on children with CA-LRTIs. This study aims to investigate the antimicrobial resistance in common bacterial agents among hospitalized children with CA-LRTIs between 2011 and 2016 in Dongguan, China.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28893195 PMCID: PMC5594502 DOI: 10.1186/s12879-017-2710-4
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1242 bacterial pathogens from 2360children with CA-LRTIs
Distributions of common bacterial pathogens in age groups
| Age | MSSA | MRSA |
|
|
|
|
|
| Others | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <1 m( | 9 (8.2) | 7 (6.3) | 8 (7.3) | 1 (0.9) | 12 (10.9) | 9 (8.2) | 1 (0.9) | 4 (4.1) | 22 (20.0) | 73 (66.3) |
| 1-3 m( | 36 (4.3) | 22 (2.7) | 18 (2.2) | 13 (1.6) | 12 (1.4) | 16 (1.9) | 7 (0.8) | 5 (0.7) | 21 (2.5) | 150 (18.1) |
| 4-6 m( | 6 (1.1) | 3 (0.5) | 8 (1.5) | 11 (2.0) | 8 (1.5) | 10 (1.8) | 12 (2.2) | 3 (0.5) | 13 (2.2) | 74 (13.6) |
| 7-12 m( | 1 (0.2) | 1 (0.2) | 3 (0.6) | 3 (0.6) | 1 (0.2) | 0 | 6 (1.3) | 2 (0.4) | 4 (0.8) | 21 (4.4) |
| 1-5y( | 2 (0.5) | 2 (0.5) | 2 (0.5) | 1 (0.3) | 0 | 0 | 5 (1.3) | 9 (2.3) | 3 (0.8) | 24 (6.0) |
| P value | <0.001 | <0.001 | <0.001 | 0.084 | <0.001 | <0.001 | 0.303 | 0.007 | <0.001 | <0.001 |
Resistance rates of main bacteria pathogens causing pediatric patients with CA-LRTIs to antimicrobial agents during 2011–2016 in Dongguan
| Antimicrobial agent | MSSA | MRSA |
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Penicillin (10 U) | 81.5% | 100% | – | – | – | – | 29.0% | – |
| Piperacillin (100μg) | – | – | 59.0% | 91.7% | 24.2% | 100% | – | 21.7% |
| Ampicillin (10μg) | – | – | 71.4% | 100% | 100% | 100% | – | – |
| Erythromycin (15μg) | 29.6% | 81.8% | – | – | – | – | 96.7% | – |
| Azithromycin (15μg) | 22.2% | 83.3% | – | – | – | – | – | – |
| Clarithromycin (15μg) | 34.5% | 82.8% | – | – | – | – | 93.3% | – |
| Ofloxacin (5μg) | 61.2% | 6.5% | 15.6% | 26.9% | 3.7% | 3.6% | 3.2% | 10.0% |
| Gentamicin (10μg) | 4.2% | 9.4% | 36.0% | 43.5% | 13.8% | 13.8% | – | 13.6% |
| Co-trimoxazole (1.25/23.75μg) | 4.0% | 13.3% | 48.1% | 70.8% | 75.0% | 82.1% | 90.0% | – |
| Cefazolin (30μg) | 0.0% | 100% | 32.3% | 95.7% | 36.4% | 93.5% | – | – |
| Cefuroxime (30μg) | – | 100% | 24.3% | 100% | 12.9% | 97.1% | – | – |
| Ceftriaxone (30μg) | – | – | 20.0% | 96.4% | 10.0% | 94.1% | 7.1% | – |
| Ceftazidime (30μg) | – | – | 2.9% | 12.5% | 11.1% | 67.7% | – | 13.6% |
| Cefotaxime (30μg) | – | – | 16.2% | 93.1% | 13.3% | 94.1% | 10.0% | – |
| Cefepime (30μg) | – | – | 7.7% | 29.6% | 0.0% | 44.1% | 4.2% | 4.3% |
| Vancomycin (30μg) | 0.0% | 0.0% | – | – | – | – | 0.0% | – |
| Imipenem (10μg) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |